Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Alfa-2b Versus No Treatment After Stem Cell Transplantation for Relapsing Lymphoma
NCT00003924Phase 3Unknown
- Sponsor
- Lymphoma Study Association
- Start
- Oct 1995
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of interferon alfa-2b in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Lymphoma Study Association. Primary endpoints: Relapse rate, Time to disease progression and 2 more. Status: unknown.
02
Drugs
interferon alfa-2b
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00003924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003924.